Acrivon to present ACR-2316 trial data at EORTC-NCI-AACR symposium
Tweet Send to a Friend
Acrivon Therapeutics (Nasdaq: ACRV) announced that dose escalation data from its ongoing Phase 1/2 study of ACR-2316, an oral WEE1/PKMYT1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




